Abstract
The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (2.0 × 10 6 CD34 cells/kg: 81.6%; 5.0 × 10 6 CD34 cells/kg: 32.0%) than in NHL patients (2.0 × 10 6 CD34 cells/kg: 64.8%; 5.0 × 10 6 CD34 cells/kg: 12.6%; P0.0001) and also significantly higher in HL patients (2.0 × 10 6 CD34 cells/kg: 81.5%; 5.0 × 10 6 CD34 cells/kg: 22.2%) than in NHL patients (P0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required.
| Original language | English |
|---|---|
| Pages (from-to) | 1046-1050 |
| Number of pages | 5 |
| Journal | Bone Marrow Transplantation |
| Volume | 47 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2012 |
Fingerprint
Keywords
- European centers
- lymphoma subtypes
- mobilization
- plerixafor
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. / Hübel, K.; Fresen, M. M.; Apperley, J. F.; Basak, G. W.; Douglas, K. W.; Gabriel, I. H.; Geraldes, C.; Jaksic, O.; Koristek, Z.; Kröger, N.; Lanza, F.; Lemoli, R. M.; Mikala, G.; Selleslag, D.; Worel, N.; Mohty, M.; Duarte, R. F.
In: Bone Marrow Transplantation, Vol. 47, No. 8, 08.2012, p. 1046-1050.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization
AU - Hübel, K.
AU - Fresen, M. M.
AU - Apperley, J. F.
AU - Basak, G. W.
AU - Douglas, K. W.
AU - Gabriel, I. H.
AU - Geraldes, C.
AU - Jaksic, O.
AU - Koristek, Z.
AU - Kröger, N.
AU - Lanza, F.
AU - Lemoli, R. M.
AU - Mikala, G.
AU - Selleslag, D.
AU - Worel, N.
AU - Mohty, M.
AU - Duarte, R. F.
PY - 2012/8
Y1 - 2012/8
N2 - The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (2.0 × 10 6 CD34 cells/kg: 81.6%; 5.0 × 10 6 CD34 cells/kg: 32.0%) than in NHL patients (2.0 × 10 6 CD34 cells/kg: 64.8%; 5.0 × 10 6 CD34 cells/kg: 12.6%; P0.0001) and also significantly higher in HL patients (2.0 × 10 6 CD34 cells/kg: 81.5%; 5.0 × 10 6 CD34 cells/kg: 22.2%) than in NHL patients (P0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required.
AB - The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (2.0 × 10 6 CD34 cells/kg: 81.6%; 5.0 × 10 6 CD34 cells/kg: 32.0%) than in NHL patients (2.0 × 10 6 CD34 cells/kg: 64.8%; 5.0 × 10 6 CD34 cells/kg: 12.6%; P0.0001) and also significantly higher in HL patients (2.0 × 10 6 CD34 cells/kg: 81.5%; 5.0 × 10 6 CD34 cells/kg: 22.2%) than in NHL patients (P0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required.
KW - European centers
KW - lymphoma subtypes
KW - mobilization
KW - plerixafor
UR - http://www.scopus.com/inward/record.url?scp=84864883480&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864883480&partnerID=8YFLogxK
U2 - 10.1038/bmt.2011.216
DO - 10.1038/bmt.2011.216
M3 - Article
C2 - 22080971
AN - SCOPUS:84864883480
VL - 47
SP - 1046
EP - 1050
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 8
ER -